Alis Biosciences’ plan is a familiar tactic in the private equity world, but the firm will instead be listed on the public ...

BML Capital Management, an activist investor that owns 9.9% of Elevation’s shares, is urging the company to wind down ...

The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a ...

Despite these cuts, the FDA should be able to stay above a "trigger" level that would prevent it from collecting fees from ...

Industry representatives will still be allowed at these meetings, but they will no longer have a spot on the advisory ...

Analysts are “cautiously optimistic” about Trump’s executive order, noting that changes to the IRA drug price negotiation ...

Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Losing the FDA’s senior negotiators would slow the renewal of the user fee programs “considerably,” according to policy and ...

At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ...

Kennedy is planning modifications to the Vaccines Adverse Event Reporting System to identify whether vaccines contribute to ...

With the discontinuation of danuglipron, Pfizer is now down to one clinical-stage obesity asset: the oral GIP analog ...

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...